Group 1 - Jilin Aodong Pharmaceutical Group Co., Ltd. announced that its subsidiary, Yanbian Pharmaceutical Co., Ltd., has obtained 10 "Traditional Chinese Medicine Formula Granule Listing Filing Certificates" [2] - Jilin Aodong is focusing on the development of traditional Chinese medicine formula granules in key regions and medical institutions, primarily targeting grade A hospitals while utilizing three terminals and online platforms for clinical promotion [2] - Yanbian Pharmaceutical has completed its pre-processing workshop, extraction workshop, formulation workshop, and comprehensive R&D building, with multiple production lines passing GMP compliance checks as of January 23, 2025 [2] Group 2 - Jilin Aodong will continue to implement a "pharmaceutical health + financial capital" dual-drive strategy, enhancing the synergy between industry and finance [3] - The company aims to leverage its strong pharmaceutical industry foundation, mature product matrix, and solid market competitive advantages to establish a sustainable development base [3] - Investment returns from financial activities will be reinvested into pharmaceutical R&D, production, and industry chain upgrades, fostering a positive collaboration with the pharmaceutical sector [3]

Core Viewpoint - The company adheres to a "pharmaceutical health + financial capital" dual-driven strategy, leveraging its deep pharmaceutical industry foundation and mature product matrix to maintain strong market competitiveness [1] Group 1: Company Strategy - The company emphasizes the importance of its dual-driven strategy for sustainable development, integrating pharmaceutical and financial sectors [1] - Financial investment activities are designed to support the development of the pharmaceutical industry, with investment returns primarily allocated to research, production, and upgrading of the industrial chain [1] Group 2: Future Outlook - The company aims to continue deepening the synergy between production and finance, striving for stable performance to reward investors [1]

Core Viewpoint - Jilin Aodong (000623.SZ) expects a significant increase in net profit for the fiscal year 2025, projecting a range of 2.265 billion to 2.482 billion yuan, representing a growth of 46.00% to 60.00% compared to the previous year [1] Financial Performance - The net profit attributable to shareholders is projected to be between 2.265 billion and 2.482 billion yuan, with a year-on-year growth of 46.00% to 60.00% [1] - The net profit after deducting non-recurring gains and losses is expected to be between 2.069 billion and 2.287 billion yuan, reflecting a growth of 31.56% to 45.37% year-on-year [1] - The impact of non-recurring gains and losses on net profit is estimated to be approximately 195.6893 million yuan for 2025, compared to -21.5112 million yuan in the same period of 2024 [1] Strategic Focus - The company is focusing on value management and enhancing operational quality, adhering to its corporate values of "focusing on people and specializing in medicine" [1] - The implementation of a sales-driven policy centered on "large product groups and multiple product groups" is a key strategy for growth [1] - The company is pursuing a dual-driven development model of "pharmaceutical health + financial capital" to accelerate its growth [1]

Core Viewpoint - The traditional Chinese medicine industry is currently in a significant development opportunity period, and the company aims to leverage policy and market opportunities to innovate and grow within this sector [1] Group 1: Strengthening Traditional Chinese Medicine Industry - The company originated from a state-owned deer farm and has established a standardized breeding base for Sika deer, ensuring high-quality raw materials for traditional Chinese medicine [1][2] - The company has invested over 46 million yuan in upgrading epidemic prevention facilities, maintaining a zero-positive record for brucellosis and tuberculosis since 2021 [1][2] - The company has obtained 525 registration certificates in the Chinese medicine granule sector, enhancing its influence in industry standards [2] Group 2: Research and Development Innovation - The company focuses on core material research and has increased investment in technology development, transitioning from experience-based practices to scientific decoding [2][4] - The company has developed a product cluster centered around Sika deer, including various medicinal products, creating an ecological closed loop from breeding to pharmaceutical products [2][3] - The company emphasizes the integration of research, breeding, processing, and market feedback to drive fundamental changes in production methods [4] Group 3: Financial and Capital Interaction - The company has adopted a dual-driven development model of "healthcare + financial capital," using financial resources to support long-term research and development [5][6] - The company is the largest shareholder of Guangfa Securities, which has provided significant cash flow and stability, contributing 12.43 billion yuan and 17.49 billion yuan in 2023 and 2024, respectively [6] - The company collaborates with various universities and research institutions to enhance its research capabilities and invest in promising biopharmaceutical projects [6][7]

Core Viewpoint - Jilin Aodong Pharmaceutical Group Co., Ltd. reported a significant increase in net profit despite a decline in revenue, demonstrating strong operational capabilities and strategic execution [1][4]. Financial Performance - In the first half of 2025, the company achieved operating revenue of 1.126 billion yuan, a year-on-year decrease of 20.21% - The net profit attributable to shareholders reached 1.282 billion yuan, a year-on-year increase of 138.44% [1]. Business Structure - The traditional Chinese medicine segment remains the core business, generating sales revenue of 686 million yuan, accounting for 60.90% of total revenue - The chemical drugs, chain pharmacy wholesale and retail, and health industry segments contributed sales revenues of 143 million yuan, 187 million yuan, and 83 million yuan, representing 12.73%, 16.59%, and 7.39% of total revenue, respectively [1]. Strategic Initiatives - The company is actively reforming its marketing system in the traditional Chinese medicine segment, having completed the marketing restructuring of 22 products and adjusted pricing policies for over 50 products - The company has made significant progress in its Chinese medicine formula granule business, obtaining 525 registration certificates for market access [2]. - A plan to issue convertible bonds to raise 134 million yuan for capital increase in its subsidiary, aimed at constructing a project for Chinese medicine formula granules with an annual production capacity of 2,000 tons [2]. Market Trends - The recovery of the consumer market is expected to accelerate the sales of consumer-oriented traditional Chinese medicine - Long-term growth is supported by an aging population and increasing health awareness among residents, providing a solid foundation for the industry [3]. Operational Efficiency - The company has optimized operational efficiency and adjusted regional layouts by closing some chain pharmacy stores, while enhancing brand management and deepening industry chain collaboration - The chain pharmacy business added 73,000 new members during the reporting period [3]. Asset Management - As of June 30, 2025, the company reported total assets of 34.151 billion yuan, a 3.48% increase from the beginning of the year, and net assets of 29.960 billion yuan, a 3.21% increase - The asset-liability ratio stands at 11.54%, indicating a low level within the industry [4].